The 'more GH = better' myth — why pulsatile vs sustained matters
5 min read · Uplevel editorial
The logic feels airtight. GH declines with age. The things GH supports — lean mass, fast recovery, low body fat, good sleep, resilient skin — also decline with age. Therefore, more GH should produce more of the good things and slow the decline. The athlete who tells you GH changed everything and the longevity clinic that promises restored youthfulness are both operating from this logic. It's coherent. It's also wrong in the way that most oversimplifications of endocrine biology are wrong: not in the direction of the effect but in the assumption that more is better than the right amount in the right pattern.
Growth hormone is not a static signal. It doesn't circulate at a baseline level the way thyroid hormone does. GH is released in pulses — typically six to twelve discrete bursts across a twenty-four-hour period, with the largest pulse occurring in the first slow-wave sleep episode of the night, roughly sixty to ninety minutes after sleep onset. Between those pulses, GH levels are close to undetectable in healthy adults. This pulsatility is not incidental to how GH works. It's fundamental. The receptor system — the GH receptor on peripheral cells and the hepatic receptor that converts GH signaling into IGF-1 production — is calibrated to pulsatile input.
The mechanism of receptor desensitization is the key piece. When GH receptor cells are exposed to a pulse of GH, they respond — initiating the JAK2/STAT5 signaling cascade that produces downstream effects including IGF-1 synthesis, protein synthesis, and lipolysis. When that pulse clears and GH levels drop back to near zero, the receptors reset. They're available and sensitive for the next pulse. This is how pulsatile signaling maintains receptor responsiveness over time.
Sustained GH elevation does the opposite. When receptors are exposed to prolonged, continuous GH rather than intermittent pulses, they downregulate. The cellular machinery that responds to GH internalizes or deactivates receptors as a protective response to excessive stimulation. This means that supraphysiological continuous GH — which is what exogenous HGH injection produces when used at the doses common in athletic and anti-aging circles — eventually produces a situation where circulating GH is high but the tissues it's supposed to act on are responding less efficiently. You have more of the signal and fewer functional receptors for it.
The side effects associated with exogenous HGH at supraphysiologic doses are not random. They're consequences of the biology. Fluid retention: GH and IGF-1 both promote sodium and water retention through renal mechanisms. Carpal tunnel syndrome, a notorious athlete complaint: edema in the confined space of the carpal tunnel compresses the median nerve. Joint pain and stiffness: the same fluid retention affecting synovial spaces. Insulin resistance: GH is counter-regulatory to insulin, opposing glucose uptake in peripheral tissues. At physiological pulsatile levels, this is managed — the pulses are brief enough that the counter-regulatory effect is bounded. At sustained supraphysiological levels, the effect accumulates and becomes clinically significant, producing elevated fasting glucose and, over time, impaired insulin sensitivity. There are also long-term concerns: IGF-1 promotes cellular proliferation, and sustained IGF-1 elevation at supraphysiological levels has been studied in the context of cancer risk, particularly for hormone-sensitive cancers. The data on this is not fully settled, but it's not dismissible.
None of this means GH support is without value. It means the model for how to support the GH axis well is the opposite of maximizing GH levels. The goal is restoring physiological pulsatility, not replacing it with continuous elevation.
This is exactly why GHRH analogs like sermorelin work the way they do. Sermorelin binds to the GHRH receptor on the pituitary and prompts GH release — but it does so through the same pathway that endogenous GHRH uses, and the pituitary's regulatory machinery remains active. Somatostatin, the inhibitory signal that tells the pituitary to stop producing GH, continues to respond to rising GH levels. The feedback loop that governs pulsatility is intact. Sermorelin can't produce sustained supraphysiological GH levels, not because of some intrinsic limitation in its potency, but because the system it's working through won't allow it. The somatostatin response kicks in and dampens the pulse before it reaches supraphysiological territory. This is a structural safety feature, not an accidental consequence.
CJC-1295 without DAC operates similarly — short-acting, pulse-amplifying, feedback-governed. The GHRH analogs as a class, when given at appropriate doses and intervals, are designed to work with pulsatility rather than against it.
The longer-acting options complicate this picture. CJC-1295 with DAC has a half-life of six to eight days. A single injection maintains GH-stimulating activity for nearly a week. The GH secretion this produces is not truly continuous — the pituitary continues to respond pulsatilly — but the baseline stimulus is sustained in a way that blunts the valleys between natural pulses and raises the GH floor. Whether this sustained elevation has the same receptor-desensitization consequences as exogenous HGH is debated; the mechanism of action is different enough that the comparison isn't direct. But the departure from physiological pulsatility is real and should be acknowledged.
MK-677, the orally bioavailable ghrelin receptor agonist with a roughly twenty-four-hour half-life, presents the clearest trade-off in this category. It reliably raises GH and IGF-1, it's convenient, and it's frequently used. It also produces relatively sustained GHS-R1a activation, which drives persistent appetite stimulation — one of the most commonly reported side effects and a direct consequence of sustained ghrelin receptor engagement. The glucose handling effects are documented: MK-677 produces measurable decreases in insulin sensitivity in a way that reflects the metabolic cost of sustained GH elevation. The dose-response curve is not linear. Doubling the dose doesn't double the benefit; it moves meaningfully into the territory of metabolic side effects.
The insight that should come from understanding pulsatility is this: the question to bring to a prescribing provider is not "how do I maximize my GH levels" but rather "how do I restore my GH pulsatility toward what it was at its best." Those are different questions with different answers. The first leads toward exogenous HGH and supraphysiological dosing — with the side effects and risks that come with it. The second leads toward GHRH analogs and appropriately dosed GHRP combinations that work with the body's own regulatory systems rather than bypassing them. The physiology that makes GH powerful is inseparable from the pulsatility that delivers it correctly. Engineering around that pulsatility doesn't give you more of the benefit. It gives you more of the compound and less of what you were actually looking for.
Frequently asked